


Cat No. 26-A39

Masitinib (AB1010)

10 mg

Masitinib (AB1010) is a protein tyrosine kinase inhibitor. It targets c-KIT, PDGFR and FGFR3. Masitinib has been shown to enhance the antiproliferative effects of gemcitabine (GEM) in human pancreatic cancer cells. It also potently inhibits human and murine KIT with activating mutations in the juxtamembrane domain. *In vivo*, Masitinib has been shown to block tumor growth in mice with subcutaneous grafts of Ba/F3 cells expressing a juxtamembrane KIT mutant. Masitinib is currently an oncology drug under clinical trial.

TECHNICAL INFORMATION



Other Names: AB1010, Masitinib mesylate

Chemical Formula: C₂₈H₃₀N₆OS

CAS Number: 790299-79-5

Molecular Weight: 498.64

Purity: >99%

Appearance: crystalline solid

Solubility: DMSO



For research purposes only

STORAGE AND HANDLING

Storage: Store at 4°C and protected from light. Following reconstitution, store aliquots at -20°C.

Stability: Stock solutions stable at -20°C for up to 2 years.

Shipping Conditions: Shipped at room temperature.

PRODUCT USE

Soluble in DMSO at 200mg/ml. If precipitate is observed, vortex for 5 minutes. For most cells, the maximum tolerance to DMSO is less than 0.5%.

REFERENCES

1. Dubreuil et al. (2009) Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT. *PLoS One*. 4(9):e7258.
2. Humbert et al. (2010) Masitinib combined with standard gemcitabine chemotherapy: in vitro and in vivo studies in human pancreatic tumour cell lines and ectopic mouse model. *PLoS One*. 5(3):e9430.
3. Lennartsson et al. (2005) Normal and oncogenic forms of the receptor tyrosine kinase kit. *Stem Cells*. 23(1): 16-43.